European journal of clinical investigation
-
Eur. J. Clin. Invest. · Jul 2023
ALKBH1 contributes to renal cell carcinoma progression by reducing N6-methyladenine of GPR137.
Renal cell carcinoma (RCC) accounts for approximately 4% of all adult malignancies with high mortality worldwide. Although conventional chemotherapy and radiotherapy treatment has been applied for RCC in clinic, the mortality rate of patients is increasing each year, and patients with metastatic RCC are still suffering from poor prognosis. Thus, further investigation of the molecular mechanisms responsible for the development and progression of RCC is of particular importance. ⋯ Our results indicate that ALKBH1-GPR137 axis might be used as a potential therapeutic target in RCC, contributing to finding new prognostic biomarkers for RCC at an early stage.
-
Eur. J. Clin. Invest. · Jul 2023
Metabolomic Profiles in Serum and Urine Uncover Novel Biomarkers in Children with Nephrotic Syndrome.
Nephrotic syndrome is common in children and adults worldwide, and steroid-sensitive nephrotic syndrome (SSNS) accounts for 80%. Aberrant metabolism involvement in early SSNS is sparsely studied, and its pathogenesis remains unclear. Therefore, the goal of this study was to investigate the changes in initiated SSNS patients-related metabolites through serum and urine metabolomics and discover the novel potential metabolites and metabolic pathways. ⋯ With untargeted metabolomics analysis and further targeted quantitative analysis, we found seven metabolites may be new biomarkers for risk prediction and early diagnosis for SSNS.
-
Eur. J. Clin. Invest. · Jul 2023
A score for predicting invasive pulmonary aspergillosis in immunocompetent critically ill patients.
Delayed treatment leads to increased mortality in critically ill patients with invasive pulmonary aspergillosis (IPA). We aimed to develop and validate a prediction score based on novel biomarkers and clinical risk factors to identify IPA in immunocompetent patients in the intensive care unit (ICU). ⋯ A score based on six clinical and novel immunological biomarkers showed promising predictive value for antifungal treatment in immunocompetent ICU patients.
-
Eur. J. Clin. Invest. · Jul 2023
Review Meta AnalysisEvaluation of Heart Failure Admission as a Surrogate for Mortality in Randomized Clinical Trials: A Meta-Analysis.
Heart failure (HF) admission is used as a study endpoint in clinical trials. However, it remains unclear whether it can be a valid surrogate endpoint for mortality. ⋯ Our findings indicate that HF admission may not always be a valid surrogate for mortality in patients with HF. Rather, the surrogacy of HF admission may be dependent on clinical background and interventions.